LT5354B - Ląstelių linijų išskyrimo baltymų neturinčioje terpėje būdas ir šiuo būdu išskirtos ląstelių linijos - Google Patents
Ląstelių linijų išskyrimo baltymų neturinčioje terpėje būdas ir šiuo būdu išskirtos ląstelių linijos Download PDFInfo
- Publication number
- LT5354B LT5354B LT2005053A LT2005053A LT5354B LT 5354 B LT5354 B LT 5354B LT 2005053 A LT2005053 A LT 2005053A LT 2005053 A LT2005053 A LT 2005053A LT 5354 B LT5354 B LT 5354B
- Authority
- LT
- Lithuania
- Prior art keywords
- protein
- protein concentration
- cell line
- cells
- medium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 114
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 114
- 210000002966 serum Anatomy 0.000 claims abstract description 12
- 239000012634 fragment Substances 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 97
- 239000002609 medium Substances 0.000 claims description 52
- 239000001963 growth medium Substances 0.000 claims description 20
- 210000004962 mammalian cell Anatomy 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 14
- 230000003833 cell viability Effects 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 8
- 230000035899 viability Effects 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 239000004017 serum-free culture medium Substances 0.000 claims description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 239000012894 fetal calf serum Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 3
- 230000030833 cell death Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 230000006978 adaptation Effects 0.000 abstract description 24
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- XPAOKCSHUNYPBS-XSBNNCSWSA-N [(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3r,5s)-3-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl] hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)[C@@H](CO)C1 XPAOKCSHUNYPBS-XSBNNCSWSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20020239A CU23097A1 (es) | 2002-10-23 | 2002-10-23 | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2005053A LT2005053A (en) | 2006-04-25 |
| LT5354B true LT5354B (lt) | 2006-07-25 |
Family
ID=40134843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2005053A LT5354B (lt) | 2002-10-23 | 2005-05-19 | Ląstelių linijų išskyrimo baltymų neturinčioje terpėje būdas ir šiuo būdu išskirtos ląstelių linijos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20060036082A1 (ru) |
| EP (2) | EP2363418B1 (ru) |
| JP (1) | JP4674087B2 (ru) |
| KR (1) | KR101186048B1 (ru) |
| CN (1) | CN1714147B (ru) |
| AR (1) | AR041645A1 (ru) |
| AT (1) | ATE502103T1 (ru) |
| AU (1) | AU2003273727B2 (ru) |
| CA (1) | CA2503315C (ru) |
| CU (1) | CU23097A1 (ru) |
| DE (1) | DE60336415D1 (ru) |
| DK (1) | DK1564285T3 (ru) |
| EA (1) | EA007465B1 (ru) |
| EC (1) | ECSP055740A (ru) |
| ES (2) | ES2360049T3 (ru) |
| GE (1) | GEP20084444B (ru) |
| HK (1) | HK1084414A1 (ru) |
| HR (1) | HRP20050760A2 (ru) |
| LT (1) | LT5354B (ru) |
| LV (1) | LV13361B (ru) |
| MY (1) | MY144088A (ru) |
| NZ (1) | NZ540171A (ru) |
| PE (1) | PE20040552A1 (ru) |
| PT (1) | PT1564285E (ru) |
| TN (1) | TNSN05116A1 (ru) |
| UY (1) | UY28037A1 (ru) |
| WO (1) | WO2004038010A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| CN104673754B (zh) * | 2015-02-14 | 2018-03-02 | 百泰生物药业有限公司 | 重组骨髓瘤细胞克隆的筛选方法及由此获得的抗体分子 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991005240A1 (en) | 1989-09-29 | 1991-04-18 | Atomic Energy Of Canada Limited | Infrared-based gas detector |
| US5393668A (en) | 1991-09-11 | 1995-02-28 | Hans-Wilhelm Doerr | Cultivation of mammalian cells in a protein-free medium on a polyvinylformal and/or polyvinyl butyral surface |
| WO1996015231A2 (en) | 1994-11-10 | 1996-05-23 | Immuno Aktiengesellschaft | Method for producing biologicals in protein-free culture |
| WO1996026266A1 (en) | 1995-02-23 | 1996-08-29 | Quest International B.V. | Peptides for tissue and cell culture media |
| WO1997019111A2 (es) | 1995-11-17 | 1997-05-29 | Centro De Inmunologia Molecular (Cim) | Anticuerpos monoclonales anti-cd6 y sus utilizaciones |
| JP2696001B2 (ja) | 1991-04-15 | 1998-01-14 | 財団法人化学及血清療法研究所 | 組換え蛋白質産生用培地 |
| US5891996A (en) | 1972-09-17 | 1999-04-06 | Centro De Inmunologia Molecular | Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3694263A (en) * | 1970-10-23 | 1972-09-26 | Joseph J Korn Sr | Swimming pool cleaning methods and apparatus therefor |
| US3886616A (en) * | 1972-12-06 | 1975-06-03 | Fay A Hayes | Hand propelled swimming pool cleaner |
| US4275474A (en) * | 1979-04-30 | 1981-06-30 | Woodard Randle C | Vacuum head for swimming pool cleaning system |
| US4240174A (en) * | 1979-07-30 | 1980-12-23 | Scott Jeffrey L | Self-contained mobile pool cleaning apparatus |
| US4430214A (en) * | 1982-09-15 | 1984-02-07 | Baker Marvin E | Strainer mill for swimming pool pump intake |
| AU2986484A (en) * | 1983-06-27 | 1985-01-03 | Monash University | Leptospira strains grown in protein free medium |
| US4558479A (en) * | 1984-01-26 | 1985-12-17 | Alopex Industries, Inc. | Pool cleaner |
| US4683599A (en) * | 1984-03-30 | 1987-08-04 | Fahet Nv | Automatic pool cleaner fitting |
| US4581075A (en) * | 1985-03-15 | 1986-04-08 | Maxi-Sweep, Inc. | Self-propelled water borne pool cleaner |
| EP0784684B8 (en) * | 1994-09-16 | 2008-03-26 | Cancer Research Institute of Contra Costa | RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES |
| AUPN442295A0 (en) | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
-
2002
- 2002-10-23 CU CU20020239A patent/CU23097A1/es unknown
-
2003
- 2003-10-10 PE PE2003001035A patent/PE20040552A1/es not_active Application Discontinuation
- 2003-10-16 AR ARP030103776A patent/AR041645A1/es active IP Right Grant
- 2003-10-17 MY MYPI20033959A patent/MY144088A/en unknown
- 2003-10-22 WO PCT/CU2003/000012 patent/WO2004038010A1/es active IP Right Grant
- 2003-10-22 NZ NZ540171A patent/NZ540171A/en not_active IP Right Cessation
- 2003-10-22 GE GEAP20038815A patent/GEP20084444B/en unknown
- 2003-10-22 EP EP11155076.0A patent/EP2363418B1/en not_active Expired - Lifetime
- 2003-10-22 DK DK03757654.3T patent/DK1564285T3/da active
- 2003-10-22 JP JP2004545689A patent/JP4674087B2/ja not_active Expired - Lifetime
- 2003-10-22 ES ES03757654T patent/ES2360049T3/es not_active Expired - Lifetime
- 2003-10-22 DE DE60336415T patent/DE60336415D1/de not_active Expired - Lifetime
- 2003-10-22 AU AU2003273727A patent/AU2003273727B2/en not_active Expired
- 2003-10-22 US US10/532,269 patent/US20060036082A1/en not_active Abandoned
- 2003-10-22 CN CN2003801036918A patent/CN1714147B/zh not_active Expired - Lifetime
- 2003-10-22 EP EP03757654A patent/EP1564285B1/en not_active Expired - Lifetime
- 2003-10-22 PT PT03757654T patent/PT1564285E/pt unknown
- 2003-10-22 ES ES11155076.0T patent/ES2624279T3/es not_active Expired - Lifetime
- 2003-10-22 CA CA2503315A patent/CA2503315C/en not_active Expired - Lifetime
- 2003-10-22 KR KR1020057006995A patent/KR101186048B1/ko active IP Right Grant
- 2003-10-22 AT AT03757654T patent/ATE502103T1/de active
- 2003-10-22 EA EA200500695A patent/EA007465B1/ru not_active IP Right Cessation
- 2003-10-23 UY UY28037A patent/UY28037A1/es not_active Application Discontinuation
-
2005
- 2005-04-22 TN TNP2005000116A patent/TNSN05116A1/en unknown
- 2005-04-22 EC EC2005005740A patent/ECSP055740A/es unknown
- 2005-05-19 LT LT2005053A patent/LT5354B/lt not_active IP Right Cessation
- 2005-05-23 LV LVP-05-61A patent/LV13361B/en unknown
- 2005-09-02 HR HR20050760A patent/HRP20050760A2/xx not_active Application Discontinuation
-
2006
- 2006-04-13 HK HK06104515.2A patent/HK1084414A1/xx not_active IP Right Cessation
-
2010
- 2010-04-13 US US12/759,208 patent/US20100197011A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891996A (en) | 1972-09-17 | 1999-04-06 | Centro De Inmunologia Molecular | Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use |
| WO1991005240A1 (en) | 1989-09-29 | 1991-04-18 | Atomic Energy Of Canada Limited | Infrared-based gas detector |
| JP2696001B2 (ja) | 1991-04-15 | 1998-01-14 | 財団法人化学及血清療法研究所 | 組換え蛋白質産生用培地 |
| US5393668A (en) | 1991-09-11 | 1995-02-28 | Hans-Wilhelm Doerr | Cultivation of mammalian cells in a protein-free medium on a polyvinylformal and/or polyvinyl butyral surface |
| WO1996015231A2 (en) | 1994-11-10 | 1996-05-23 | Immuno Aktiengesellschaft | Method for producing biologicals in protein-free culture |
| WO1996026266A1 (en) | 1995-02-23 | 1996-08-29 | Quest International B.V. | Peptides for tissue and cell culture media |
| WO1997019111A2 (es) | 1995-11-17 | 1997-05-29 | Centro De Inmunologia Molecular (Cim) | Anticuerpos monoclonales anti-cd6 y sus utilizaciones |
Non-Patent Citations (2)
| Title |
|---|
| MATEO C. ET AL.: "Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity", HYBRIDOMA, 2000, pages 463 - 471 |
| REITER M ET AL.: "Flow cytometry and two-dimensional electrophoresis (2-DE) for system evaluation of long term continuous perfused animal cell cultures in macroporous beads", CYTOTECHNOLOGY, 1992, pages 247 - 253 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK169586B1 (da) | Histil ukendt rottemyelomacellelinie, hybridcellelinie afledt deraf, in vitro cellekultursystem og cellefusionssystem omfattende celler herfra, fremgangsmåde til fremstilling af en hybridcellelinie samt fremgangsmåde til fremstilling af monoklonale antistoffer | |
| AR011439A2 (es) | Procedimiento para producir quimeras de inmunoglobulina (ig) del receptor del factor de necrosis tumoral (tnfr), nuevas preparaciones igg1 del tnfr1 yuna composicion terapeutica que los contiene | |
| EP0043718A2 (en) | Improvements in or relating to cell lines | |
| AU2015211514A1 (en) | Method for modulating galactosylation of recombinant protein through optimization of culture medium | |
| JP2017516484A (ja) | タンパク質生産のための細胞培養工程 | |
| LT5354B (lt) | Ląstelių linijų išskyrimo baltymų neturinčioje terpėje būdas ir šiuo būdu išskirtos ląstelių linijos | |
| ES2908067T3 (es) | Métodos para modular los perfiles de galactosilación proteicos de proteínas recombinantes empleando peracetil galactosa | |
| EP0251106A2 (en) | Improved fusion method | |
| EP0251107A2 (en) | Improved fusion products | |
| BRPI0315565B1 (pt) | Método para se obter uma linhagem celular de mieloma nso que contém uma sequência que codifica um polipeptídeo recombinante ou uma proteína recombinante adaptada para crescer em meio livre de soro e proteína, e, uso do método | |
| US20230348850A1 (en) | Cell culture processes | |
| CN111373028B (zh) | 蛋白质的生产方法 | |
| JPS60204727A (ja) | 抗ヒトｖ型コラ−ゲン抗体 | |
| Ali et al. | Serum Free Culture of Human-Human Hybridoma Secreting Monoclonal Antibodies Against Stomach Cancer | |
| JPS61219381A (ja) | ヒト−ヒトハイブリド−マ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20131022 |